Chinese biotech companies censored And Claiming Crown Could Experimental drug agencies

being able to have the potential, an experimental drug from Gilead Sciences, a Chinese biotechnology company, claims to manage the production of the new coronavirus, it was censored for the dissemination of inaccurate information. The Shanghai Stock Exchange, said in a statement on Sunday that the brilliant Bio-Medical Technology Gene did not win approval, to make the drug of Chinese regulators drugs known as remdesivir, is seen as the leading candidate in the race, a treatment for the virus to find, is now disgusted about 88,000 and killed more than 3,000. bright genes has not been authorized by the patent holder – Gilead – to make the drug, yet it has received “appropriate qualifications” for the mass production of the therapy, the stock exchange said. The stocks fell by the daily limit of 20% intraday on Monday. Gilead’s investigational drug that has not been licensed or approved for use anywhere in the world is being tested in clinical trials in hospitals in the central Chinese city of Wuhan, the epicenter of the outbreak crown, as well as in other countries Asian. Sign up for our daily newsletter crown by clicking on this link, and send any tips, leads and [email protected] stories. ad luminous genes on February 12 that remdesivir production had created in large quantities, collected the titles of the world and sent the shares by almost 60% last month to touch a record high. The complaint comes as trade concerns that researchers and drug manufacturers to grow in China and elsewhere to address the growing epidemic on the global panic grab attention get for less than credible scientific work. bright genes, for example, had only been able remdesivir in a small amount for clinical research and non-commercial production and its omission of this difference to the spread to make “unclear, inaccurate information,” he said on the stock exchange. Light Gene-board secretary Wang Zhengye, interviews with the local media have been saying the drug company is not only for use in the laboratory, but for mass production, was also censured by the exchange. With the virus now reported in more than 65 countries, the exuberance of investors and medical societies around the development of treatments and vaccines run the risk of being and divert resources from more important irrational scientific work. Concerns nearly 300 clinical trials were also studying in China, the effectiveness of various treatments Crown Gilead remdesivir and Abbvie Inc. Anti-HIV treatment with Kaletra to traditional Chinese medicine and soy milk. The design and execution of some of these studies have raised concerns among scientists, according to an article published last week in the Chinese Journal of Epidemiology. The wave of studies has also led a race for patients as test subjects, potentially delaying the progress of serious research that could lead to the discovery of effective therapies. World Health Organization, Deputy Director General Bruce Aylward asked priority researchers the most promising studies last week, saying that the Chinese researchers are facing difficulties in patient enough processes to recruit remdesivir, he said, is the only drug which can be effective. “We do many other studies with things that are less promising,” he said.
Picture copyright by Yifan Ding-Getty Images